由于成本上升,雇主限制昂贵的减重药品的覆盖面,而特朗普政府则提议将肥胖症重新归类为慢性疾病,以扩大获得治疗的机会。 Employers are limiting coverage for costly weight-loss drugs due to rising costs, while the Trump administration proposes reclassifying obesity as a chronic disease to expand access.

由于成本上升,雇主越来越多地重新评价诸如Ozempic和Wegovy等昂贵的GLP-1减重药品的覆盖率,43%的大公司现在的覆盖率从2024年的28%上升至2024年的28%,而只有16%的小雇主这样做。 Employers are increasingly reevaluating coverage for expensive GLP-1 weight-loss drugs like Ozempic and Wegovy due to rising costs, with 43% of large firms now offering coverage—up from 28% in 2024—while only 16% of smaller employers do so. 财政紧张促使一些人限制基于BMI的准入,或要求参与体重管理方案。 The financial strain is prompting some to limit access based on BMI or require participation in weight management programs. 同时,特朗普政府提议将肥胖症重新归类为《医疗保健计划》下的一种慢性病,有可能扩大获得这些药物的机会,并降低自付费用,这也可以减少在医疗监督下使用糖尿病和心脏病的风险。 Meanwhile, the Trump administration proposes reclassifying obesity as a chronic disease under Medicare, potentially expanding access and lowering out-of-pocket costs for these medications, which can also reduce risks for diabetes and heart disease when used with medical oversight.